Correction of ischemic damage to the retina on application of pharmacological preconditioning of recombinant erythropoietin

Abstract

To study the protective properties of pharmacological preconditioning with recombinant erythropoietin suberitro stimulating dose of 50 IU / kg in the retina of the eye, was the model of retinal ischemia, ischemia with the assessment of the temporary simulation mode of the retina of rats with the instrumental methods of analysis and morphometric studies. The most suitable model was a model 30 minute ischemia with subsequent reperfusion periods of 1 hour to 72 hours. We studied the protective effect preconditioning suberitro stimulating recombinant erythropoietin in a dose of 50 IU/kg, preconditioning distant ischemic and emoxipine 2 mg/kg per rat model of retinal ischemia. In the experiment, it was revealed that the recombinant erythropoietin (50 IU/kg) prevents the development of degenerative retinal layers due to ischemic damage more than distant ischemic preconditioning and emoxipine. The observed protective effect of erythropoietin us with the development of ischemia was confirmed by laser Doppler flowmetry, electroretinography and morphometry. Using suberitro stimulating recombinant erythropoietin in a dose of 50 IU/kg, 30 minutes prior to the pathology simulation eliminates erythropoietic effect, and the lack of positive dynamics in groups with preliminary administration of glibenclamide 5 mg/kg, the key role of ATP-dependent potassium channels in a preconditioning mechanism implementation. Identification and use of pharmacological agents, which have the effect of preconditioning, may be a new approach in the correction and prevention of retinal ischemia, which is the leading element in the pathogenesis of a number of visual pathologies. The possibility of pharmacological preconditioning with erythropoietin ischemic lesions of the retina is essential for the development of anti-ischemic agents for the treatment and prevention of ocular pathologies of ischemic origin.